دورية أكاديمية

The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review and meta-analysis.

التفاصيل البيبلوغرافية
العنوان: The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review and meta-analysis.
المؤلفون: Garg A; Division of Ophthalmology, Department of Surgery, McMaster University, Hamilton, Ontario, Canada., Nanji K; Division of Ophthalmology, Department of Surgery, McMaster University, Hamilton, Ontario, Canada; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada., Tai F; Division of Ophthalmology, Department of Surgery, McMaster University, Hamilton, Ontario, Canada., Phillips M; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada., Zeraatkar D; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada., Garg SJ; Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, PA, USA., Sadda SR; Department of Ophthalmology, David Geffen School of Medicine at University of California, Los Angeles, CA, USA; Doheny Eye Institute, Los Angeles, CA, USA., Kaiser PK; Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA., Guymer RH; Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia; Department of Surgery (Ophthalmology), University of Melbourne, Melbourne, Australia., Sivaprasad S; Institute of Ophthalmology, University College London, UK; NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK., Wykoff CC; Retina Consultants of Texas, Houston, TX, USA; Blanton Eye Institute, Houston Methodist Hospital, Houston, TX, USA., Chaudhary V; Division of Ophthalmology, Department of Surgery, McMaster University, Hamilton, Ontario, Canada; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada. Electronic address: vchaudh@mcmaster.ca.
المصدر: Survey of ophthalmology [Surv Ophthalmol] 2024 May-Jun; Vol. 69 (3), pp. 349-361. Date of Electronic Publication: 2023 Nov 24.
نوع المنشور: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review
اللغة: English
بيانات الدورية: Publisher: Elsevier Science Country of Publication: United States NLM ID: 0404551 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-3304 (Electronic) Linking ISSN: 00396257 NLM ISO Abbreviation: Surv Ophthalmol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: New York, NY : Elsevier Science,
مواضيع طبية MeSH: Complement C3*/metabolism , Complement C3*/antagonists & inhibitors , Complement C5*/antagonists & inhibitors , Complement Inactivating Agents*/therapeutic use , Geographic Atrophy*/drug therapy , Geographic Atrophy*/diagnosis , Geographic Atrophy*/etiology , Geographic Atrophy*/physiopathology, Humans ; Macular Degeneration/drug therapy ; Visual Acuity
مستخلص: With the introduction of therapies to treat geographic atrophy (GA), GA management in clinical practice is now possible. A living systematic review can provide access to timely and robust evidence synthesis. This review found that complement factor 3 and 5 (C3 and C5) inhibition compared to sham likely reduces change in square root GA area at 12 months and untransformed GA area at 24 months. There is likely little to no difference in the rate of systemic treatment-emergent adverse events compared to sham. C3 and C5 inhibition, however, likely does not improve best-corrected visual acuity (BCVA) at 12 months, and the evidence is uncertain regarding change in BCVA at 24 months. Higher rates of ocular treatment emergent adverse effects with complement inhibition occur at 12 months and likely at 24 months. Complement inhibition likely results in new onset neovascular age-related macular degeneration at 12 months. This living meta-analysis will continuously incorporate new evidence.
Competing Interests: Declaration of Competing Interest None.
(Copyright © 2023. Published by Elsevier Inc.)
معلومات مُعتمدة: R01 EY030614 United States EY NEI NIH HHS
فهرسة مساهمة: Keywords: Age-related macular degeneration; Avacincaptad pegol; C3; C5; Complement; Eculizumab; Geographic atrophy; Living systematic review; Meta-analysis; Pegcetacoplan
المشرفين على المادة: 0 (Complement C3)
0 (Complement C5)
0 (Complement Inactivating Agents)
تواريخ الأحداث: Date Created: 20231126 Date Completed: 20240427 Latest Revision: 20240710
رمز التحديث: 20240710
DOI: 10.1016/j.survophthal.2023.11.008
PMID: 38008405
قاعدة البيانات: MEDLINE
الوصف
تدمد:1879-3304
DOI:10.1016/j.survophthal.2023.11.008